Showing results (141-150 of 188) with videos related to
Sort By:
Pageof 19
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 1993
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysisE E Vokes, M E Dolan, S Krishnasamy, et al.Cancer Chemotherapy and Pharmacology|January 1, 1997
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorinG F Fleming, S M O'Brien, P C Hoffman, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2005
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumorsA A Desai, R L Schilsky, A Young, et al.The Pharmacogenomics Journal|May 7, 2002
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityL Iyer, S Das, L Janisch, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 1997
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 scheduleM J Ratain, L A Skoog, S M O'Brien, et al.Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusionR L Schilsky, M J Ratain, L Janisch, et al.Clinical Pharmacology and Therapeutics|February 28, 2013
Estimation of renal cell carcinoma treatment effects from disease progression modelingM L Maitland, K Wu, M R Sharma, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B studyR C Lilenbaum, A A Miller, G Batist, et al.Leukemia & Lymphoma|July 28, 2016
Low Dose Interferon Alfa-2B for the Induction of Remission of Hairy Cell Leukemia: A Multi-institutional Study of 49 PatientsH M Golomb, M J Ratain, A Fefer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1993
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysisE E Vokes, M J Ratain, R Mick, et al.Pageof 19